139 related articles for article (PubMed ID: 11000611)
1. Molecular prognostic markers in pancreatic cancer.
Coppola D
Cancer Control; 2000; 7(5):421-7. PubMed ID: 11000611
[TBL] [Abstract][Full Text] [Related]
2. Molecular aspects of carcinogenesis in pancreatic cancer.
Koliopanos A; Avgerinos C; Paraskeva C; Touloumis Z; Kelgiorgi D; Dervenis C
Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):345-56. PubMed ID: 18693168
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.
Rachagani S; Macha MA; Heimann N; Seshacharyulu P; Haridas D; Chugh S; Batra SK
Adv Drug Deliv Rev; 2015 Jan; 81():16-33. PubMed ID: 25453266
[TBL] [Abstract][Full Text] [Related]
4. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective.
Sakorafas GH; Tsiotou AG; Tsiotos GG
Cancer Treat Rev; 2000 Feb; 26(1):29-52. PubMed ID: 10660490
[TBL] [Abstract][Full Text] [Related]
5. Molecular prognostic markers in pancreatic cancer: a systematic review.
Garcea G; Neal CP; Pattenden CJ; Steward WP; Berry DP
Eur J Cancer; 2005 Oct; 41(15):2213-36. PubMed ID: 16146690
[TBL] [Abstract][Full Text] [Related]
6. [Etiology and carcinogenesis of pancreatic ductal adenocarcinoma].
Song SY
Korean J Gastroenterol; 2008 Feb; 51(2):71-83. PubMed ID: 18349569
[TBL] [Abstract][Full Text] [Related]
7. Identifying molecular markers for the early detection of pancreatic neoplasia.
Goggins M
Semin Oncol; 2007 Aug; 34(4):303-10. PubMed ID: 17674958
[TBL] [Abstract][Full Text] [Related]
8. Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma.
Costache MI; Iordache S; Costache CA; Dragos E; Dragos A; Saftoiu A
J Gastrointestin Liver Dis; 2017 Mar; 26(1):51-57. PubMed ID: 28338114
[TBL] [Abstract][Full Text] [Related]
9. Role of tumour markers, cytogenetics.
Lamerz R
Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809
[TBL] [Abstract][Full Text] [Related]
10. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer.
Qin R; Smyrk TC; Reed NR; Schmidt RL; Schnelldorfer T; Chari ST; Petersen GM; Tang AH
Br J Cancer; 2015 Feb; 112(3):514-22. PubMed ID: 25584484
[TBL] [Abstract][Full Text] [Related]
11. High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients.
Leppänen J; Helminen O; Huhta H; Kauppila JH; Isohookana J; Haapasaari KM; Lehenkari P; Saarnio J; Karttunen TJ
Virchows Arch; 2017 Apr; 470(4):401-410. PubMed ID: 28191612
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
[TBL] [Abstract][Full Text] [Related]
13. Molecular prognostic markers in pancreatic cancer.
Ghaneh P; Kawesha A; Evans JD; Neoptolemos JP
J Hepatobiliary Pancreat Surg; 2002; 9(1):1-11. PubMed ID: 12021893
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of p21-activated kinase 4 in resected pancreatic cancer.
Park S; Kim JW; Kim H; Kim JW; Kim YJ; Lee KW; Kim JH; Kim JH; Hwang JH; Choi YR; Cho JY; Yoon YS; Han HS
APMIS; 2017 Aug; 125(8):699-707. PubMed ID: 28556956
[TBL] [Abstract][Full Text] [Related]
15. Molecular biology of pancreatic cancer: how useful is it in clinical practice?
Sakorafas GH; Smyrniotis V
JOP; 2012 Jul; 13(4):332-7. PubMed ID: 22797383
[TBL] [Abstract][Full Text] [Related]
16. Role of hypermethylation on carcinogenesis in the pancreas.
Kuroki T; Tajima Y; Kanematsu T
Surg Today; 2004; 34(12):981-6. PubMed ID: 15580378
[TBL] [Abstract][Full Text] [Related]
17. The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression.
Hawa Z; Haque I; Ghosh A; Banerjee S; Harris L; Banerjee SK
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27240340
[TBL] [Abstract][Full Text] [Related]
18. [Tumour markers of pancreatic cancer--Part II (molecular markers of carcinogenesis and non-specific tumour markers)].
Groblewska M; Mroczko B; Karpiuk E; Szmitkowski M
Pol Arch Med Wewn; 2005 Nov; 114(5):1118-27. PubMed ID: 16789513
[No Abstract] [Full Text] [Related]
19. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment.
Singh P; Srinivasan R; Wig JD
Pancreas; 2011 Jul; 40(5):644-52. PubMed ID: 21673535
[TBL] [Abstract][Full Text] [Related]
20. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
